NCT02984644View on ClinicalTrials.gov

Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 6, 2017

Primary Completion Date

November 16, 2018

Study Completion Date

November 16, 2019

Conditions
Type II; Diabetes
Interventions
DRUG

Dapagliflozin

Three 5-hour measurements (after dapagliflozin 10mg administration) of endogenous glucose production (EGP) will be performed on separate days.

DRUG

Placebo

Three 5-hour measurements (after placebo administration) of endogenous glucose production (EGP) will be performed on separate days.

Trial Locations (1)

78229

University of Texas Health Science Center, San Antonio

All Listed Sponsors
lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT02984644 - Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin | Biotech Hunter | Biotech Hunter